🇺🇸 FDA
Pipeline program

Placebo to match 10 mg, Placebo to match 5 mg

CB8025-41837

Phase 3 small_molecule active

Quick answer

Placebo to match 10 mg, Placebo to match 5 mg for Primary Biliary Cholangitis is a Phase 3 program (small_molecule) at Gilead Sciences International Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Gilead Sciences International Limited
Indication
Primary Biliary Cholangitis
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials